Skip to main content
. 2021 Dec 2;16(12):e0259301. doi: 10.1371/journal.pone.0259301

Fig 3. ILV/mIL12 provides protection against distant, non-injected tumors.

Fig 3

Mice were inoculated with (A-C) B16 melanoma tumors in both of their footpads (1E6 cells, n = 8), (D-F) B16 melanoma tumors subcutaneously in both of their flanks (1E5 cells, n = 10) or (G-I) CT26 colon carcinoma tumors subcutaneously in both of their flanks (1E5 cells, n = 9), then treated with ILV/mIL-12 in the right flank tumor when tumors were palpable (Day 7–10), leaving the left flank tumor untreated (F, p < 0.0001; J, p < 0.02; representative data from 5 independent experiments) (J, K) Mice were inoculated orthotopically with a single 4T1 mammary carcinoma tumor their mammary fat pad, then treated with ILV/mIL12 intratumorally (n = 8). Mouse lungs were isolated to count metastatic lung nodules 18 days after inoculation (p = 0.0008, representative data from 3 independent experiments). Tumor growth plots represent individual tumors on each mouse. Survival benefit was determined using Mantel-Cox Log-rank testing where p < 0.05 is considered significant. Data points and error bars in K represent mean and standard error of the mean, respectively. A Student’s T-test was used to determine significance.